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The aims of this study were as follows. First, we sought to compare the in vitro susceptibility
of liposomal amphotericin B (LAmB) and anidulafungin on Candida albicans and Candida
glabrata biofilms growing on silicone discs. Second, we sought to compare the activity of
LAmB versus anidulafungin for the treatment of experimental catheter-related C. albicans
and C. glabrata infections with the antifungal lock technique in a rabbit model.
Methods
Two C. albicans and two C. glabrata clinical strains were used. The minimum biofilm eradi-
cation concentration for 90% eradication (MBEC90) values were determined after 48h of
treatment with LAmB and anidulafungin. Confocal microscopy was used to visualize the
morphology and viability of yeasts growing in biofilms. Central venous catheters were
inserted into New Zealand rabbits, which were inoculated of each strain of C. albicans and
C. glabrata. Then, catheters were treated for 48h with saline or with antifungal lock tech-
nique using either LAmB (5mg/mL) or anidulafungin (3.33mg/mL).
Results
In vitro: anidulafungin showed greater activity than LAmB against C. albicans and C. glab-
rata strains. For C. albicans: MBEC90 of anidulafungin versus LAmB: CA176, 0.03 vs. 128
mg/L; CA180, 0.5 vs. 64 mg/L. For C. glabrata: MBEC90 of anidulafungin versus LAmB:
CG171, 0.5 vs. 64 mg/L; CG334, 2 vs. 32 mg/L. In vivo: for C. albicans species, LAmB and
anidulafungin achieved significant reductions relative to growth control of log10 cfu recov-
ered from the catheter tips (CA176: 3.6±0.3 log10 CFU, p�0.0001; CA180: 3.8±0.1 log10
CFU, p�0.01). For C. glabrata, anidulafungin lock therapy achieved significant reductions
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Conclusions
For the C. albicans strains, both LAmB and anidulafungin may be promising antifungal lock
technique for long-term catheter-related infections; however, anidulafungin showed signifi-
cantly higher activity than LAmB against the C. glabrata strains.
Introduction
Candida spp. are the fourth most common cause of nosocomial bloodstream infection (BSI)
worldwide with an incidence of 8.1 cases/100 000 inhabitants in Spain during the years 2010–
2011 and an attributable mortality rate of 31%.[1]
Although Candida albicans remains globally the most common fungal isolate from blood,
substantial increases in the prevalence of non-albicans Candida spp. have been reported, with
proportions of 45 and 55%, respectively.[1,2] Cases of non-albicans Candida BSI are com-
monly caused by Candida parapsilosis (24.9%), Candida glabrata (13.4%) and Candida tropica-
lis (7.7%).[1,2]
Central venous catheters (CVCs) appear to be the most common risk factor for the devel-
opment of candidemia in patients without neutropenia or major immunodeficiencies.
These infections are closely related to the ability of Candida to form biofilms on artificial
surfaces.[3,4] This ability poses an important therapeutic issue because fungal cells encased
in biofilms are known to display a reduced susceptibility to antifungals compared to their
planktonic counterparts.[4] The treatment of long-term catheter-related BSI (CRBSI)
caused by Candida spp. requires the removal of the catheter and in addition to systemic
treatment with fluconazole or an echinocandin for two weeks,[5,6] although some studies
have noted that the impact of this practice has failed to improve the outcome in subgroups
of patients.[7] On the other hand, catheter removal is not always possible (i.e., in subsets of
patients who have a surgically implantable catheter with no other available vascular access
or who have profound thrombocytopenia); thus, the need arises for a therapeutic option
that allows the conservative management of the catheter-related infection, such as the anti-
fungal lock technique (ALT), which consists of locking catheters with a high concentration
of an antifungal solution.[8] This conservative strategy would be useful in select circum-
stances, for example, in uncomplicated cases in which catheters are infected with Candida
spp. but are greatly needed or unsafe to remove.
Few investigations published to date have been focused on the in vivo usefulness of ALT to
treat C. albicans and C. glabrata catheter-related infections.[9] According to The Infectious
Diseases Society of America (IDSA),[6] the data are insufficient to support specific recommen-
dations for the use of ALT for catheter salvage in the management of CRBSI caused by Can-
dida spp.
This study had two purposes. The first purpose was to assess the in vitro susceptibility of C.
albicans and C. glabrata growing on silicone discs to LAmB and anidulafungin, and the second
purpose was to assess the effectiveness of anidulafungin at 3.33 mg/mL compared with LAmB
at 5 mg/mL for the treatment of experimentally induced C. albicans and C. glabrata catheter-
related infections by the antifungal lock technique.
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Materials and methods
Strains
Four well-characterized biofilm-producing Candida spp. strains were used. Two C. albicans
(CA176 and CA180) and two C. glabrata (CG171 and CG334) strains were isolated from
patients with CRBSI. For quality control, the ATCC C. parapsilosis 22019 reference strain was
used. The strains were stored at -80˚C in skim milk.
Antifungals
Liposomal amphotericin B (LAmB) was provided by Gilead Sciences, Inc. (Madrid, Spain),
and anidulafungin was provided by Pfizer, Inc. (Madrid, Spain). For the in vivo animal model
of infection, the concentrations used were 5 mg/mL for LAmB and 3.33 mg/mL for anidula-
fungin. These concentrations were the highest possible due to the concentration provided in
the commercial drug vial. The drug dilutions were prepared according to the manufacturers’
instructions. The treatments were supplemented with 100 IU/mL of sodium heparin.
In vitro studies
Susceptibility studies. The MICs of LAmB and anidulafungin for the two C. albicans and
the two C. glabrata strains were determined by the broth microdilution method according to
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines and
breakpoints.[10] For the biofilm formation assay, we followed the protocol described by Chan-
dra et al.,[11] with slight modifications. The C. albicans and C. glabrata strains were grown
overnight in Yeast Nitrogen Base medium (Sigma-Aldrich Co., Madrid, Spain) with 50 mM
dextrose (YNBD) at 37˚C with continuous shaking at 60 rpm. After centrifugation, the cul-
tures were washed twice with sterile PBS (pH 7.2) and were resuspended at a final concentra-
tion of 1�107 blastoconidia/mL. Then, inocula were applied to 12-well plates, and silicone
elastomer discs (15 mm diameter x 1.5 mm; Merfasa SL, Barcelona, Spain) were added. The sil-
icone discs were incubated for 90 min at 37˚C and were then placed in a new plate containing
brain heart infusion (BHI; Becton, Dickinson and Company, Le Pont de Claix, France)
medium. These plates were incubated for 48 h at 37˚C with continuous shaking at 60 rpm. The
silicone discs that contained the fungal biofilm were placed on a new plate containing various
two-fold dilutions of LAmB and anidulafungin and were incubated at 37˚C for 48 h. For the
evaluation of the minimum biofilm eradication concentration for 90% eradication (MBEC90),
the silicone discs were placed in a new plate with fresh BHI. The biofilm was scraped (Sarstedt,
Inc., Newton, NC, USA) and serially diluted, and the yeast cells were enumerated by the viable
count method. The MBEC90 was defined as the minimum concentration of antimicrobial
required to reduce the biofilm cell numbers (relative to the initial inoculum size) by�90%.
[12] All experiments were performed in triplicate.
Confocal laser scanning microscopy assay. The effect of different concentrations of
LAmB and anidulafungin on the growth of C. albicans and C. glabrata biofilm on silicone
discs was visualized using confocal laser scanning microscopy (CLSM) with an Olympus
FV1000 microscope with excitation wavelengths of 488 and 568 nm. To grow the biofilms on
the silicone discs, yeast cells were cultured in BHI at 37˚C while being shaken for 48 h, as
described previously.[11] Then, biofilms were treated for 48 h with LAmB or anidulafungin at
37˚C. Afterwards, the biofilms were stained using a LIVE/DEAD BacLight Viability Kit
(Molecular Probes, Invitrogen, Leiden, The Netherlands). Briefly, this technique consisted of
staining the cells encased in the biofilm with a mixture of SYTO 9 (3.34 mM solution in
DMSO) and propidium iodide (20 mM solution in DMSO) and incubating at room
Antifungal lock therapy for C. albicans and C. glabrata
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temperature in the dark for 30 min to distinguish between dead cells and cells that remained
alive after antifungal exposure. Three areas of the biofilm on each silicone disc were scanned
with a 2 μm step size. Simultaneous dual-channel imaging was used to display the green and
red fluorescence. The IMARIS 8 software (Bitplane, Belfast, UK) was used to create a projec-
tion view of the formed biofilms, and the ImageJ 1.45s software package (developed at the
National Institutes of Health, Bethesda, USA) was used to calculate the percentage of green
(live) and red (dead) pixels. All experiments were performed in triplicate.
In vivo studies
Ethics statement. This study was carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health and the ARRIVE Guidelines (Animal Research: Reporting of In vivo Experiments) (S1
and S2 files), and all efforts were made to minimize suffering. The experimental protocol was
approved by the Animal Experimentation Ethics Committee of Vall d’Hebron Research Insti-
tute (registration number 73.12 CEEA) and the Ministry of Environment of the Catalan Gov-
ernment (registration number 7863).
Catheter-related infection model. The animal model was based on our previous studies.
[12] New Zealand white male rabbits (Granja Riera, Barcelona, Spain) weighing 2.0 to 2.2 kg
were singly housed under a reversed 12 h/12 h light/dark cycle with water and food ad libitum
throughout the experiment. Briefly, animals were anaesthetized by intramuscular injection of
100 mg/kg ketamine plus 20 mg/kg xylazine. Then, a catheter made of sterile silicone tubing
(SILASTIC, ID/OD: 0.45/0.77 inch, Dow Corning Corporation, MI, USA) was inserted into
the internal jugular vein at a depth of up to 8 cm and secured with silk suture. After placement,
the catheters were inoculated with 0.35 mL of a suspension containing 1�107 blastoconidia/mL
of either C. albicans or C. glabrata strains. The inoculum was locked in the lumen of the cathe-
ter for 48 h and was carefully withdrawn by aspiration immediately before starting ALT. The
treatment groups were as follows: untreated control (normal saline), LAmB at 5 mg/mL and
anidulafungin at 3.33 mg/mL. The catheters were locked with 0.4 mL of each treatment for 48
h. At the end of the treatment period, the animals were euthanized with intravenous pentobar-
bital, and the catheters were removed for microbiological evaluation. The distal 4 cm of each
catheter was cut, submerged in BHI and sonicated at 50 Hz for 10 min for quantitative culture.
The sonication products were washed twice by centrifugation, and the pellet was serially
diluted, plated, and incubated on Sabouraud agar (Sigma-Aldrich Co., Madrid, Spain) plates
for 48 h at 37˚C. After incubation, a colony count was performed. The results were expressed
as log10 total colony-forming units (CFU).
Statistical analysis. The catheters yielding negative results were compared. The percent-
age of negative cultures obtained in each treatment was analysed using Fisher’s exact test, and
the mean of log10 CFU recovered from the catheter tips was compared using one-way
ANOVA and Tukey’s post-hoc test. Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS, Inc., Chicago, IL, USA) version 16 package program. P-




Susceptibility studies. The results of the susceptibility study can be seen in Table 1; the C.
albicans and C. glabrata isolates used in our study were susceptible to both LAmB and
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anidulafungin, according to the interpretation of susceptibility defined by the most recent
EUCAST breakpoints.[10]
Anidulafungin was>1000-fold more effective than LAmB against both C. albicans strains
growing on silicone discs (MBEC90 anidulafungin vs. MBEC90 LAmB: CA176, 0.03 vs. 128
mg/L; CA180, 0.5 vs. 64 mg/L).
For the C. glabrata strains growing on silicone discs, anidulafungin was>10 and>100-fold
more effective than LAmB against the CG171 and CG334 strains, respectively (MBEC90 anidu-
lafungin vs. MBEC90 LAmB: CG171, 0.5 vs. 64 mg/L; CG334, 2 vs. 32 mg/L).
Confocal laser scanning microscopy assay. CLSM was used to visualize the morphology
and viability of Candida spp. growing on silicone discs for 48 h using a LIVE/DEAD staining
technique. Figs 1(A), 1(B), 2(A) and 2(B) represent the percentage of viable cells after 48 h of
treatment against the tested strains of C. albicans and C. glabrata, respectively.
At high concentrations, LAmB and anidulafungin had similar effects on the reduction of
cell viability in the biofilms of both C. albicans strains. The reduction in cell viability due to
treatment with anidulafungin at 3333 mg/L approached or exceeded 90% for both the CA176
(Fig 1A) and CA180 (Fig 1B) strains; LAmB at 5000 mg/L had a similar effect.
Regarding the C. glabrata strains, the effects of high concentrations of LAmB and anidula-
fungin were different for the two strains studied. Anidulafungin at 3333 mg/L demonstrated
better efficacy (87% cell death) than LAmB at 5000 mg/L against the CG171 strain (Fig 2A). In
contrast, LAmB and anidulafungin had a similar effect (cell death greater than 90%) against
the CG334 strain (Fig 2B). Note that in response to anidulafungin at a low concentration of
0.06 mg/L, the reduction in C. glabrata viability was greater than 70% for both strains (CG171:
70%; CG334: 96%).
The visualization of Candida spp. morphology by CLSM (Figs 1C and 2C: 60x magnifica-
tion) revealed small, ovoid colonies in the groups treated with different concentrations of
LAmB and high concentrations of anidulafungin; this morphology was the same as that
observed in the growth control group. Interestingly, we observed a large, globose morphology
in the C. albicans strains when biofilms of these strains were treated with low concentrations
of anidulafungin, suggesting a structural defect in the cell surface of these strains. However,
this effect was not observed in the C. glabrata strains.
In vivo studies
Catheter-related infection model. The results obtained from the rabbit catheter tip cul-
tures after sonication and centrifugation are shown in Table 2. For catheter-related infection
due to either strain of C. albicans, the fungal load recovered from the catheter tips in both the
anidulafungin- or LAmB-lock therapies treated animals and the untreated control animals was
similar (CA176: 3.6 ± 0.3 log10 CFU, p� 0.0001; CA180: 3.8 ± 0.1 log10 CFU, p� 0.01). How-
ever, there were differences between the two strains with respect to the negativization of the
Table 1. In vitro susceptibility of Candida albicans and Candida glabrata strains to LAmB and anidulafungin.
LAmB Anidulafungin
Strain MIC (mg/L) MBEC90 (mg/L) MIC (mg/L) MBEC90 (mg/L)
C. albicans CA176 0.5 128 0.0017 0.03
CA180 0.5 64 0.0035 0.5
C. glabrata CG171 1 64 0.015 0.5
CG334 0.5 32 0.007 2
LAmB, Liposomal Amphotericin B; MIC, minimum inhibitory concentration; MBEC90, minimum biofilm eradication concentration for 90% eradication.
https://doi.org/10.1371/journal.pone.0212426.t001
Antifungal lock therapy for C. albicans and C. glabrata
PLOS ONE | https://doi.org/10.1371/journal.pone.0212426 February 19, 2019 5 / 11
catheter tips. In the rabbits infected with the CA176 strain, only half of the catheters in the
LAmB lock therapy group were sterile (control group: 0%; anidulafungin group: 40%; p� 0.05
vs. untreated control group). In the animals infected with the CA180 strain, the anidulafungin-
and LAmB-lock therapies achieved the same rate of catheter tip negativization as did no treat-
ment (83% in both treatments, p� 0.01).
In the animals infected with either strain of C. glabrata, the colony counts from the catheter
tips after 48 h of antifungal lock therapy were significantly lower in the animals treated with
lock therapy with anidulafungin than in those treated with lock therapy with LAmB (CG171,
p� 0.05; CG334, p� 0.01). Compared with no treatment, lock therapy with anidulafungin at
3.33 mg/mL resulted in a significant reduction in CFU recovered from the catheter tips; this
reduction was more than 4.8 log10 CFU for both strains of C. glabrata (CG171: 4.8 log10 CFU,
p� 0.0001; CG334: 5.1 log10 CFU, p� 0.0001). Note that anidulafungin at 3.33 mg/mL was
the only antifungal treatment that resulted in a significant percentage of negative catheter
Fig 1. Viability assay for biofilms of Candida albicans strains. (A) Viability of strain CA176. (B) Viability of strain CA180. (C) LIVE/DEAD fluorescence
imaging of strains CA176 and CA180. LAmB, Liposomal Amphotericin B; AFG, anidulafungin.
https://doi.org/10.1371/journal.pone.0212426.g001
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cultures for both strains after 48 h: 64% for strain CG171 (control: 0%; LAmB 5 mg/mL: 21%;
p� 0.05) and 100% for strain CG334 (control: 0%; LAmB 5 mg/mL: 29%; p� 0.01).
Discussion
Focusing on the in vitro MBEC90 assays, we found that anidulafungin was more effective than
LAmB against C. albicans and C. glabrata biofilms growing on silicone discs. In contrast, we
obtained different results in the cell viability tests. Both anidulafungin at 3.33 mg/mL and
LAmB at 5 mg/mL had a similar efficacy (cell death >90%) against C. albicans strains. In con-
trast, against C. glabrata, anidulafungin demonstrated better efficacy than LAmB against the
CG171 strain, and both treatments (anidulafungin and LAmB) achieved a similar effect against
the CG334 strain (cell death >90%).
Rapid salvage after catheter-related infection is likely to be clinically important because it
allows earlier access to long-term catheters, thereby improving patient outcomes. This rapid
Fig 2. Viability assay for biofilms of Candida glabrata strains. (A) Viability of strain CG171. (B) Viability of strain CG334. (C) LIVE/DEAD fluorescence
imaging of strains CG171 and CG334. LAmB, Liposomal Amphotericin B; AFG, anidulafungin.
https://doi.org/10.1371/journal.pone.0212426.g002
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salvage effect was obtained by lock therapy with either 3.33 mg/mL of anidulafungin or 5 mg/
mL of LAmB for 48 h in our experimental model of C. albicans catheter-related infection.
Note that although both antifungals decreased the fungal load in the catheters infected with
the two strains of C. albicans, a significant sterilization of the catheter tips was only achieved
for one of the two strains studied. In contrast, in the experimental model of C. glabrata cathe-
ter-related infection, lock therapy with anidulafungin resulted in a significant reduction in
fungal load recovered from the catheter tips compared to that achieved by LAmB for both
strains. Likewise, only anidulafungin treatment resulted in negative catheter tip cultures.
These data are in accordance with our previous published study, in which lock therapy with
anidulafungin showed the highest activity against experimental catheter-related C. parapsilosis
infection.[12] Our study thus identifies ALT as a fast and highly effective treatment that is an
alternative to catheter removal for those selected cases; however, the ALT regimen assessed in
our study is Candida species-dependent.
Our results are similar to those reported in an experimental model of C. albicans infection,
which demonstrated no difference between ALT with caspofungin or LAmB;[13–15] however,
Schinabeck et al.,[13] Chandra et al.,[14] and Shuford et al.[15] demonstrated catheter sterili-
zation after 7 days of ALT with LAmB, deoxycholate AmB (dAmB), or caspofungin. Our stud-
ies only treat with ALT for 48 h because we believe that rapid clearance of the pathogen in an
infected central venous catheter would likely be clinically important. In contrast to earlier find-
ings, which argue that there were no differences between ALT with caspofungin or LAmB
against C. glabrata isolates, our model of ALT demonstrates paradoxical behaviour of C. glab-
rata biofilms on the catheters in response to LAmB and anidulafungin.
In general, the published in vitro data have shown that dAmB and echinocandins such as cas-
pofungin or micafungin have high activity against C. albicans and C. glabrata growing in bio-
films.[16] Nevertheless, anidulafungin and lipid formulations of AmB have been rarely
investigated using in vitro susceptibility biofilm models. Oncu et al.[17] tested the effect of
dAmB compared with caspofungin against C. albicans on silicone catheter segments and dem-
onstrated complete growth inhibition. Ramage et al.[18] and Kawai et al.[19] demonstrated a
dose-dependent activity of LAmB against C. albicans and C. glabrata biofilms, a result similar to
that observed in our study. Also in accordance with our findings, Cateau et al.[20]
Table 2. Results of antifungal lock therapy for Candida albicans and Candida glabrata strains.
Treatment C. albicans C. glabrata



















mean ± SD (95%
CI)
Control 0/10 (0) 5.1 ± 0.5 (4.8–5.5) 0/4 (0) 4.0 ± 1.0 (2.5–5.5) 0/10 (0) 5.7 ± 0.4 (5.5–6.1) 0/7 (0) 5.1 ± 0.7 (4.4–5.8)
LAmB 5 mg/
mL
5/10 (50) a 1.2 ± 1.3 (0.2–2.0) b 5/6 (83) c 0.3 ± 0.8 (0.5–1.2) c 3/14 (21) 2.1 ± 1.2 (1.4–2.8) b 2/7 (29) 1.4 ± 1.0 (0.4–2.3) b
AFG 3.33
mg/mL
4/10 (40) 1.8 ± 1.5 (0.7–2.9) b 5/6 (83) c 0.2 ± 0.7 (0.4–1.0) c 7/11 (64) c d 0.9 ± 1.3 (0.1–1.8) b
d
8/8 (100) b e 0.0 ± 0.0 (0.0–0.0) b
e
The results are given as the ratio of the negative catheter cultures to the total number of catheters (expressed as percentages), and the median total CFU (expressed in
log10 CFU). LAmB, Liposomal amphotericin B; AFG, Anidulafungin.
ap � 0.05 vs. control
bp � 0.0001 vs. control
cp � 0.01 vs. control.
dp � 0.05 vs. LAmB.
ep� 0.01 vs. LAmB.
https://doi.org/10.1371/journal.pone.0212426.t002
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demonstrated the efficacy of 48 h of echinocandin (caspofungin and micafungin) treatment
against young and mature biofilms of C. albicans and C. glabrata on silicone catheter segments.
Our results show that after exposing biofilms of C. albicans and C. glabrata growing on sili-
cone discs to different concentrations of LAmB and anidulafungin, the MBEC90 antifungal con-
centration of obtained after the discs were scraped and cultivated in Sabouraud agar was lower
than the viability observed with the LIVE/DEAD technique and visualized with CLSM. This find-
ing is in agreement with the results of Salma et al.,[21] which showed the existence of a viable but
nonculturable (VBNC) state in S. cerevisiae. The concept of a VNBC state has been thoroughly
studied in bacteria but not in yeast, and our study is the first to describe such a state in Candida
spp. This phenomenon is characterized by the ability of the cells to maintain detectable metabolic
activity but an inability to grow on culture media, and it arises as the result of the stress response;
in this case, the stress is a result of exposure to antifungals. The recovery of cultivability is possible
if the stress is removed, but only if the cells were in this state for a short period of time.
Few data have been published regarding the conservative management of CRBSI caused by
Candida spp. in humans. Imbert et al.[16] have recently reviewed the literature discussing the
antifungal solutions used for lock therapy and have reported all of the clinical studies with C.
albicans and C. glabrata. Regarding cases of catheter-related C. albicans infection; 5 out of 5
patients treated with ALT using dAmB at 2 to 2.5 mg/mL demonstrated catheter salvage,[22–
24] and Buckler et al.[25] achieved a catheter salvage rate of 50% (1 out of 2 cases) using lock
therapy with LAmB at 2.67 mg/mL. Four cases of catheter-related C. glabrata infection using
lock therapy with AmB have been reported;[23] only 1 out 3 cases achieved catheter salvage
using dAmB at 2.5 mg/mL, and one patient was treated and cured by using ALT with dAmB at
5 mg/mL. Interestingly, the literature does not report the use of anidulafungin-lock therapy to
treat catheter-related C. albicans or C. glabrata infection.
In conclusion, ALT with anidulafungin provided a fast decrease in biofilm-embedded con-
centrations of C. albicans and C. glabrata and resulted in negative catheter tip cultures after 48 h
of treatment in the majority of animals. For catheter-related C. albicans infection, ALT with
either anidulafungin or Liposomal Amphotericin B was equally effective in eradicating infec-
tion, although one of the two tested strains did not attain negative catheter cultures at 48 h. Nev-
ertheless, against C. glabrata, only ALT with anidulafungin at 3.33 mg/mL resulted in a high
percentage of negative catheter tip cultures at the critical time point of 48 h; thus, this regimen
may be useful as an antifungal lock therapy in the treatment of catheter-related infection due to
C. glabrata. The results of this study support lock therapy with anidulafungin at 3.33 mg/L or
Liposomal Amphotericin B at 5 mg/L as an adjunctive therapeutic option to systemic treatment
in selected cases of long-term CRBSI caused by C. albicans. In patients with long-term CRBSI
caused by C. glabrata, we recommend anidulafungin as an elective antifungal lock therapy.
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